Restart Life Sciences Corp. NMLSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 603.19% | -42.56% | 8.75% | 39.33% | 84.62% |
| Depreciation & Amortization | 2,133.33% | 866.67% | -25.00% | -25.00% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 732.89% | -30.25% | 8.68% | 39.00% | 83.90% |
| Operating Income | -521.40% | 51.32% | -8.68% | -39.00% | -83.90% |
| Income Before Tax | -399.32% | 58.33% | -112,900.00% | -145.47% | -122.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -399.32% | 58.33% | -112,900.00% | -145.47% | -122.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -399.32% | 58.33% | -112,900.00% | -145.47% | -122.21% |
| EBIT | -521.40% | 51.32% | -8.68% | -39.00% | -83.90% |
| EBITDA | -522.16% | 51.47% | -8.75% | -39.33% | -84.62% |
| EPS Basic | -175.00% | 80.28% | -- | -118.94% | 2.22% |
| Normalized Basic EPS | -252.38% | 75.47% | 55.00% | 41.67% | 25.00% |
| EPS Diluted | -100.00% | 65.73% | -- | -133.18% | 1.37% |
| Normalized Diluted EPS | -252.38% | 75.47% | 50.00% | 38.24% | 25.00% |
| Average Basic Shares Outstanding | 80.85% | 111.43% | 135.62% | 141.96% | 126.86% |
| Average Diluted Shares Outstanding | 80.85% | 111.43% | 112.37% | 134.20% | 126.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |